/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Ionis Pharmaceuticals (IONS) generated about $874 million in revenue and -$565 million in net income (a -64.7% net margin) over the trailing twelve months, growing at roughly 5.3% a year. Figures are from SEC filings; this is analysis, not investment advice.
Ionis Pharmaceuticals generated about $874 million in revenue over the trailing twelve months. Revenue has grown at roughly 5.3% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Ionis Pharmaceuticals reported about -$565 million in net loss over the trailing twelve months, a net margin of roughly -64.7%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Ionis Pharmaceuticals runs a gross margin of about 123.0%, an operating margin of about -68.0%, a net margin of about -64.7%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Ionis Pharmaceuticals's revenue has compounded at roughly 5.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside IONS's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 29 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 30 Jul 2026. How this is calculated.
Fiscal year ends Dec.